Feb 27, 2026 06:20AM
Jan 13, 2026 12:19PM
Nov 7, 2025 08:50AM
Nov 7, 2025 08:42AM
Apr 24, 2025 02:14AM
Jul 26, 2024 06:46AM
Jun 10, 2024 04:54PM Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Apr 24, 2024 01:00AM
Feb 13, 2024 04:08PM
Aug 16, 2023 03:32PM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Jul 19, 2023 12:42PM
Jun 28, 2023 08:00PM Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
Jun 14, 2023 04:35PM
Jun 14, 2023 02:21PM
Jun 13, 2023 01:10PM
Jun 12, 2023 01:00AM
May 26, 2023 08:20AM
Apr 27, 2023 01:00AM
Mar 16, 2023 02:02PM Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
Mar 2, 2023 02:13PM
Feb 9, 2023 01:00AM
Jan 27, 2023 01:00AM
Jan 20, 2023 10:00AM
Jan 9, 2023 01:00AM
Dec 23, 2022 05:00PM
Nov 9, 2022 06:57AM Ipsen Announces Onivyde Regimen Demonstrated Statistically Significant Improvement in OS in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Nov 9, 2022 01:01AM
Oct 27, 2022 12:57AM
Oct 25, 2022 10:20AM
Aug 12, 2022 11:35AM
Aug 3, 2022 01:00AM
Aug 1, 2022 01:00AM
Jul 28, 2022 12:57AM Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
Jun 29, 2022 01:00AM
Jun 27, 2022 01:01AM
Jun 27, 2022 01:00AM
May 3, 2022 01:00AM
Mar 25, 2022 08:44AM
Mar 16, 2022 02:30AM
Feb 11, 2022 01:00AM Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
Dec 17, 2021 01:00AM
Oct 21, 2021 01:36AM
Aug 13, 2021 01:00AM
Jul 29, 2021 01:00AM
Jun 28, 2021 06:17AM
Jun 28, 2021 01:00AM
Jun 28, 2021 01:00AM Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previo
Jun 7, 2021 08:04AM

322,223 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All